&lt;p&gt;Circulating miR-15a and miR-222 as Potential Biomarkers of Type 2 Diabetes&lt;/p&gt;

Sadeghzadeh, Salman; Ashkezari, Mahmood Dehghani; Seifati, Seyed Morteza; Mehrjardi, Mohammad Yahya Vahidi; Tezerjani, Masoud Dehghan; Sadeghzadeh, Sara; Ladan, Seyed Amir Behtash

doi:10.2147/dmso.s263883

Cited by 15 publications

(7 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results indicated that TC and miR-222-3p acted as the independent risk factors for CVD in PCOS non-ow patients. The deregulation of miR-222 expression is implicated in a series of DM and CVD [ 32 , 33 ]. Collectively, high expression of miR-222-3p was correlated with increased risks of diabetic and cardiovascular diseases in PCOS patients.…”

Section: Discussionmentioning

confidence: 99%

Correlation study on serum miR-222-3p and glucose and lipid metabolism in patients with polycystic ovary syndrome

et al. 2022

View full text Add to dashboard Cite

Objective microRNAs (miRNAs) play pivotal roles in polycystic ovary syndrome (PCOS), an endocrine and metabolic disorder that commonly occurs in women of childbearing age. This paper aimed to measure miR-222-3p expression in sera of PCOS patients and to explore its clinical value on PCOS diagnosis and prediction of diabetic and cardiovascular complications. Methods Totally 111 PCOS patients and 94 healthy people were recruited and assigned to the overweight (ow) group and non-overweight (non-ow) group, followed by determination of serum miR-222-3p expression. The diagnostic efficiency of miR-222-3p on PCOS ow and non-ow patients was analyzed. Correlations between miR-222-3p and glycolipid metabolic indicators and diabetic and cardiovascular complications in PCOS were analyzed. The downstream target of miR-222-3p was predicted and their binding relationship was verified. The correlation between PGC-1α and miR-222-3p was analyzed. Results miR-222-3p was highly-expressed in PCOS patients (p < 0.001), in especially PCOS ow patients. The area under the curve (AUC) of miR-222-3p diagnosing PCOS non-ow patients was 0.9474 and cut-off value was 1.290 (89.06% sensitivity, 98.11% specificity), indicating that non-ow people with serum miR-222-3p > 1.290 could basically be diagnosed with PCOS. AUC of miR-222-3p diagnosing PCOS ow patients was 0.9647 and cut-off value was 2.425 (85.11% sensitivity, 100% specificity), suggesting that ow people with serum miR-222-3p > 2.425 could basically be diagnosed with PCOS. miR-222-3p was positively-correlated with fasting plasma glucose (FPG), fasting insulin (FINS), homeostatic model assessment–insulin resistance (HOMA-IR), and low-density lipoprotein cholesterol (LDL-C) and negatively-correlated with high-density lipoprotein cholesterol (HDL-C). miR-222-3p was independently-correlated with diabetic and cardiovascular complications in PCOS (p < 0.05). High expression of miR-222-3p predicted high risks of diabetic and cardiovascular complications in PCOS. miR-222-3p targeted PGC-1α and was negatively-correlated with PGC-1α (r = − 0.2851, p = 0.0224; r = − 0.3151, p = 0.0310). Conclusion High expression of miR-222-3p assisted PCOS diagnosis and predicted increased risks of diabetic and cardiovascular complications. miR-222-3p targeted PGC-1α and was negatively-correlated with PGC-1α.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation study on serum miR-222-3p and glucose and lipid metabolism in patients with polycystic ovary syndrome

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Among the selected miRNAs, miR-15-5p, miR-375-3p and miR-21-5p are associated to insulin production in pancreatic β-cells. A significant downregulation of miR-15a-5p has been demonstrated in pre-diabetes and T2D, representing a useful tools to predict the onset of the disease and to differentiate subjects with alteration of glycemic metabolism from healthy controls [51]. Moreover, plasma levels of miR-15a-5p correlate with disease severity [52].…”

Section: Discussionmentioning

confidence: 99%

Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study

Formichi

Fignani

Nigi

et al. 2021

IJMS

View full text Add to dashboard Cite

Type 2 diabetes (T2D) represents one of the major health issues of this century. Despite the availability of an increasing number of anti-hyperglycemic drugs, a significant proportion of patients are inadequately controlled, thus highlighting the need for novel biomarkers to guide treatment selection. MicroRNAs (miRNAs) are small non-coding RNAs, proposed as useful diagnostic/prognostic markers. The aim of our study was to identify a miRNA signature occurring in responders to glucagon-like peptide 1 receptor agonists (GLP1-RA) therapy. We investigated the expression profile of eight T2D-associated circulating miRNAs in 26 prospectively evaluated diabetic patients in whom GLP1-RA was added to metformin. As expected, GLP1-RA treatment induced significant reductions of HbA1c and body weight, both after 6 and 12 months of therapy. Of note, baseline expression levels of the selected miRNAs revealed two distinct patient clusters: “high expressing” and “low expressing”. Interestingly, a significantly higher percentage of patients in the high expression group reached the glycemic target after 12 months of treatment. Our findings suggest that the evaluation of miRNA expression could be used to predict the likelihood of an early treatment response to GLP1-RA and to select patients in whom to start such treatment, paving the way to a personalized medicine approach.

show abstract

“…Still, there are some papers describing miRNA levels in plasma or in the heart tissue of individuals suffering from MetS or T2D, which might reflect microenvironmental influence on macrophage content. For example, some authors described downregulation of miR-126, miR-15a, miR-29b, and miR-223 in the plasma of diabetic patients, of patients with CAD, and of Lep ob mice [ 36 , 37 ], whereas He et al observed downregulation of miR-21 in the serum of patients with MetS and in circulating monocytes of type 1 diabetic individuals [ 38 ]. These observations of miRNA levels in sera are in line with our data regarding cardiac macrophages.…”

Section: Discussionmentioning

confidence: 99%

A Comprehensive miRNome Analysis of Macrophages Isolated from db/db Mice and Selected miRNAs Involved in Metabolic Syndrome-Associated Cardiac Remodeling

Niderla-Bielińska

Ścieżyńska

Moskalik

et al. 2021

IJMS

View full text Add to dashboard Cite

Cardiac macrophages are known from various activities, therefore we presume that microRNAs (miRNAs) produced or released by macrophages in cardiac tissue have impact on myocardial remodeling in individuals with metabolic syndrome (MetS). We aim to assess the cardiac macrophage miRNA profile by selecting those miRNA molecules that potentially exhibit regulatory functions in MetS-related cardiac remodeling. Cardiac tissue macrophages from control and db/db mice (an animal model of MetS) were counted and sorted with flow cytometry, which yielded two populations: CD45+CD11b+CD64+Ly6Chi and CD45+CD11b+CD64+Ly6Clow. Total RNA was then isolated, and miRNA expression profiles were evaluated with Next Generation Sequencing. We successfully sequenced 1400 miRNAs in both macrophage populations: CD45+CD11b+CD64+Ly6Chi and CD45+CD11b+CD64+Ly6Clow. Among the 1400 miRNAs, about 150 showed different expression levels in control and db/db mice and between these two subpopulations. At least 15 miRNAs are possibly associated with MetS pathology in cardiac tissue due to direct or indirect regulation of the expression of miRNAs for proteins involved in angiogenesis, fibrosis, or inflammation. In this paper, for the first time we describe the miRNA transcription profile in two distinct macrophage populations in MetS-affected cardiac tissue. Although the results are preliminary, the presented data provide a foundation for further studies on intercellular cross-talk/molecular mechanism(s) involved in the regulation of MetS-related cardiac remodeling.

show abstract

<p>Circulating miR-15a and miR-222 as Potential Biomarkers of Type 2 Diabetes</p>

Cited by 15 publications

References 55 publications

Correlation study on serum miR-222-3p and glucose and lipid metabolism in patients with polycystic ovary syndrome

Correlation study on serum miR-222-3p and glucose and lipid metabolism in patients with polycystic ovary syndrome

Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study

A Comprehensive miRNome Analysis of Macrophages Isolated from db/db Mice and Selected miRNAs Involved in Metabolic Syndrome-Associated Cardiac Remodeling

Contact Info

Product

Resources

About